|Mr. David Moatazedi||Pres, CEO & Director||798.38k||N/A||1978|
|Ms. Lauren P. Silvernail||CFO & Exec. VP of Corp. Devel.||554.25k||N/A||1959|
|Mr. Michael Mazen Jafar||Chief Marketing Officer||536.58k||N/A||1981|
|Mr. Alejandro Sabad||VP of Operations||N/A||N/A||N/A|
|Mr. Ashwin K. Agarwal||VP of Fin., Investor Relations & Treasury||N/A||N/A||N/A|
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California. Evolus, Inc. is a subsidiary of ALPHAEON Corporation.
Evolus, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 6; Compensation: 10.